Abstract:BACKGROUND:Hepatitis B virus (HBV) infection is the primary cause of hepatitis with chronic HBV infection, which may develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Detection of early-stage fibrosis related to HBV infection is of great clinical significance to block the progression of liver lesion. Direct liver biopsy is regarded as the gold standard to detect and assess fibrosis; however, this method is invasive and prone to clinical sampling error. In order to address these issues, we attempted to find more convenient and effective serum markers for detecting HBV-induced early-stage liver fibrosis.AIM:To investigate serum N-glycan profiling related to HBV-induced liver fibrosis and verify multiparameter diagnostic models related to serum N-glycan changes.METHODS:N-glycan profiles from the sera of 432 HBV-infected patients with liver fibrosis were analyzed. Significant changed N-glycan levels (peaks) (P < 0.05) in different fibrosis stages were selected in the modeling group, and multiparameter diagnostic models were established based on changed N-glycan levels by logistic regression analysis. The receiver operating characteristic (ROC) curve analysis was performed to evaluate diagnostic efficacy of N-glycans models. These models were then compared with the aspartate aminotransferase to platelet ratio index (APRI) , fibrosis index based on the four factors (FIB-4), glutamyltranspeptidase platelet albumin index (S index), GlycoCirrho-test, and GlycoFibro-test. Furthermore, we combined multiparameter diagnostic models with alanine aminotransferase (ALT) and platelet (PLT) tests and compared their diagnostic power. In addition, the diagnostic accuracy of N-glycan models was also verified in the validation group of patients.RESULTS:Multiparameter diagnostic models constructed based on N-glycan peak 1, 3, 4 and 8 could distinguish between different stages of liver fibrosis. The area under ROC curves (AUROCs) of Model A and Model B were 0.890 and 0.752, respectively differentiating fibrosis F0-F1 from F2-F4, and F0-F2 from F3-F4, and surpassing other serum panels. However, AUROC (0.747) in Model C used for the diagnosis of F4 from F0-F3 was lower than AUROC (0.795) in FIB-4. In combination with ALT and PLT, the multiparameter models showed better diagnostic power (AUROC = 0.912, 0.829, 0.885, respectively) when compared with other models. In the validation group, the AUROCs of the three combined models (0.929, 0.858, and 0.867, respectively) were still satisfactory. We also applied the combined models to distinguish adjacent fibrosis stages of 432 patients (F0-F1/F2/F3/F4), and the AUROCs were 0.917, 0.720 and 0.785.CONCLUSION:Multiparameter models based on serum N-glycans are effective supplementary markers to distinguish between adjacent fibrosis stages of patients caused by HBV, especially in combination with ALT and PLT.

Practical value of serum immunoglobulins for differentiating pathological grades and stages of chronic hepatitis

The Diagnostic Value of the Fib-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis

Practical Value of Serum Biochemical Indexes for Predicting Liver Fibrosis

Practical value of serum immunoglobulins for diagnosing hepatitis B associated cirrhosis

Revaluation of Serum Fibrotic Markers for Predicting Hepatopathological Grading and Staging

Evaluation of serum HBsAg, HBcrAg and HBV DNA in prediction of the pathological status of liver in patients with chronic hepatitis B

Appraisement of Serum Immunoglobulins for Prediction of Hepatitis B Associated Cirrhosis by Binary Logistic Regression Analysis

Efficacy of serum HBsAg levels by two quantitative methods in predicting liver histopathological grading and staging in patients with chronic hepatitis B

Relationship between Pathological Grading and Staging of Chronic Liver Diseases and Serum Parameters

Evaluation on predictive value of serum HBsAg,HBcrAg and HBV DNA for liver pathology in chronic hepatitis B patients

Serological Indices and Ultrasound Variables in Predicting the Staging of Hepatitis B Liver Fibrosis: A Comparative Study Based on Random Forest Algorithm and Traditional Methods.

Value of Five Noninvasive Serum Models in the Diagnosis of Chronic Hepatitis B Liver Fibrosis

[Establishment and Preliminary Application of Serum Golgi Protein 73 Based Noninvasive Diagnostic Model for Compensated Stage Hepatitis B Cirrhosis].

The Association of Serum Immunoglobulin and Complement Levels and Liver Fibrosis and Inflammation Stage in Patients with Chronic Hepatitis B

Practical Value of Peripheral Blood Cells Count for Predicting Liver Fibrosis

Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.

Analysis of serum immune parameters of patients with chronic hepatitis B with different levels of hepatitis B viral load

Appraisement of Simple Non-Invasive Models for Predicting Hepatitis B Associated Cirrhosis by Binary Logistic Regression Analysis

Serum N-glycan Markers for Diagnosing Liver Fibrosis Induced by Hepatitis B Virus

Changes of immunoglobulin, sP-selectin and sICAM-1 in patients with different degrees of hepatitis b cirrhosis and the possible clinical significance

Evaluation on the value of ultrasonic quantitative method in diagnosing liver fibrosis in chronic hepatitis B patients